The acquisition would help MedGenome strengthen its diagnostic foothold in North India
Sequoia Capital-backed genomics-driven diagnostics and research startup MedGenome has acquired Prognosis Laboratories to expand its geographical presence.
The acquisition would help MedGenome strengthen its diagnostic foothold in North India and cater to the needs of a larger population base.
Dr Deepak Sadwani, Partner, Prognosis Laboratories believes this strategic partnership would accelerate the next phase of growth and expansion for the overall business.
Mayank Madan, Partner, Prognosis Laboratories is elated that their brand provides complimenting services which are a natural fit for MedGenome’s business. He stated, “Under MedGenome’s management, Prognosis shall have a wider market reach and recall in an otherwise crowded segment.”
Manmohan Tiwana, MD and CEO – Wodehouse Capital believes this acquisition by MedGenome is completely in line with their stated objective of democratising the access of quality and affordable genetic solutions. Prognosis’s clients will now have access to genetic testing and a wide range of industry-first genetic tests like Rhesus D, ThyroTrack, SPITal-SEQ, NIPT and many more for detection and diagnosis of complex
diseases.
